Compare CALY & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CALY | PBLS |
|---|---|---|
| Founded | 1982 | N/A |
| Country | United States | United States |
| Employees | 28000 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 3.6B |
| IPO Year | N/A | 2026 |
| Metric | CALY | PBLS |
|---|---|---|
| Price | $18.36 | $30.81 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $16.50 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 545.1K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.70 | N/A |
| Revenue Next Year | $3.01 | N/A |
| P/E Ratio | $64.24 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.26 | $25.56 |
| 52 Week High | $20.28 | $33.65 |
| Indicator | CALY | PBLS |
|---|---|---|
| Relative Strength Index (RSI) | 52.02 | 58.33 |
| Support Level | $17.74 | $26.83 |
| Resistance Level | $19.36 | $30.90 |
| Average True Range (ATR) | 0.60 | 2.46 |
| MACD | -0.13 | -0.02 |
| Stochastic Oscillator | 23.43 | 61.83 |
Callaway Golf Co is a golf equipment, gear and apparel company with a portfolio of world-wide brands, including Callaway Golf, Odyssey, TravisMathew, and OGIO. Callaway designs, manufactures, and sells high-performance golf clubs, golf balls, apparel, bags, and other accessories-setting the standard for performance in the game of golf. The company has two operating and reportable business segments: Golf Equipment and Apparel, Gear and Other. Geographically, the company operates in United States, Europe, Asia, and Rest of World, of which it derives maximum revenue from United States.
Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.